Tenofovir Disoproxil Fumarate Teva Drug Interactions

Interaction studies have only been performed in adults.
Based on the results of in vitro experiments and the known elimination pathway of tenofovir, the potential for CYP450-mediated interactions involving tenofovir with other medicinal products is low.
Concomitant use not recommended: Tenofovir disoproxil fumarate Teva Tablets should not be administered concomitantly with other medicinal products containing tenofovir disoproxil fumarate or tenofovir alafenamide.
Tenofovir Disoproxil Fumarate Teva Tablets should not be administered concomitantly with adefovir dipivoxil.
Didanosine: Co-administration of tenofovir disoproxil fumarate and didanosine is not recommended (see Precautions and Table 2).
Renally eliminated medicinal product: Since tenofovir is primarily eliminated by the kidneys, co-administration of tenofovir disoproxil fumarate with medicinal products that reduce renal function or compete for active tubular secretion via transport proteins hOAT 1, hOAT 3 or MRP 4 (e.g. cidofovir) may increase serum concentrations of tenofovir and/or the co-administered medicinal products.
Use of tenofovir disoproxil fumarate should be avoided with concurrent or recent use of a nephrotoxic medicinal product. Some examples include, but are not limited to, aminoglycosides. amphotericin B, foscarnet, ganciclovir, pentamidine, vancomycin, cidofovir or interleukin-2 (see Precautions).
Given that tacrolimus can affect renal function, close monitoring is recommended when it is co-administered with tenofovir disoproxil fumarate.
Other interactions: Interactions between tenofovir disoproxil fumarate and other medicinal products are listed in Table 2 as follows (increase is indicated as "", decrease as "", no change as "", twice daily as "b.i.d.", and once daily as "q.d."). (See Table 2.)

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image


Click on icon to see table/diagram/image


Click on icon to see table/diagram/image

Studies conducted with other medicinal products: There were no clinically significant pharmacokinetic interactions when tenofovir disoproxil fumarate was co-administered with emtricitabine, lamivudine, indinavir, efavirenz, nelfinavir, saquinavir (ritonavir boosted), methadone, ribavirin, rifampicin, tacrolimus, or the hormonal contraceptive norgestimate/ethinyl oestradiol.
Tenofovir disoproxil fumarate must be taken with food, as food enhances the bioavailability of tenofovir.